JAZZ.US Jazz Pharmaceuticals PLC

Healthcare Pharmaceuticals USA Stocks
241.55 USD
Close of Nov 15, 2026
156.95 266.38
Market cap
USD 15.5B
P/E
71.5x
P/B
3.70x
ROE
0.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is JAZZ.US undervalued?

Graham number

The Graham number of Jazz Pharmaceuticals PLC cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jazz Pharmaceuticals PLC fundamental analysis

No fundamental analysis for Jazz Pharmaceuticals PLC yet.

Jazz Pharmaceuticals PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymp…

Full company profile